|
|
Post by Clement on Oct 7, 2019 19:13:12 GMT -5
$2M per week is a run rate of $104M per year. I'll double check the net margins and cash burn, but the last time I did, this got us close. And, this not a one product company, so multiple sources of revenue. I'm counting on that plus growth in Afrezza to get us over that line, initially. The other products in development won't be generating sales by mid next year, the time frame you mentioned for break even, but yes there is potential for TreT to make a significant difference in 2021. Wrong . From slide 20 on the last earnings call, we see that it is more than 50%. In fact, net revenue is 59% of gross for 2Q 2019. As sales grow (ever so slowly) efficiencies increase and this ratio climbs as cost per unit decreases. This was explained in the earnings call. investors.mannkindcorp.com/static-files/41653254-2987-4238-98e3-057f602feb38 |
|
|
|
Post by longliner on Oct 7, 2019 19:13:36 GMT -5
I think, rossomalley, that it’s time for you to give Castagna’s statement a rest. You’re using it like a baseball bat to bludgeon PB members. Symphony scripts are traceable to writers. The two “clinics” stated is in all likelihood two physicians and MannKind’s CEO doesn’t have a clue how many physicians work for VDex. Shareholders don’t know whether the two physicians are from a startup VDex clinic or an established one. McCulloch addressed this in his public rebuttal and, at the end of the day, I simply want to see script growth. I don’t care from where. What exactly did Bill say? And why didn’t he want to offer the ‘real’ number to correct Mike’s number? Until Bill comes clean about how many NRx VDEx has generated and how many of them are still using Afrezza a year and a day later, we won’t know for sure whether they have a successful model or not. However, AFAIK we don’t know what exactly Mike was basing his numbers on. You’re the one who is trying to spin it as Symphony readouts for 2 physicians. Mike said simply that VDEX was producing less than 25 TRx per month ‘from their 2 clinics’. Maybe they only have 2 clinics producing any meaningful number of Rx. Or maybe he misspoke and meant from all of their clinics. Frankly, I don’t know that they are actually operating six clinics in any meaningful sense. Announcing them on Twitter doesn’t mean anything. Have you seen one of these ‘clinics’ with your own eyes? Has anyone here seen one? The fact remains that the 25 TRx is one of the few numbers we have to work with until Bill decides to be transparent about VDEX numbers. The other number we have came from VDEX itself and that number (a total 300 patients for all their clinics since the beginning) is hardly reassuring. I too just want Rx to increase and I too will be happy to get them from wherever (as long as it’s not one-and-done Rx, which I think could be a problem if VDEX is overly dependent on discount programs like this year’s DTC). However when VDEX became a distracting and costly nuisance factor for MannKind with this HFM nonsense, and now that they’re using their social media minions to suggest VDEX is responsible for every pop in weekly Rx, then I start feeling that they are undermining my MNKD investment, not helping it. So, if Bill is really helping MannKind move Afrezza, let him prove it. Mr. Bill, open those books! I believe Bill indicated a willingness to pursue SEC action against us as well. At the time I struggled to see how this action, as a Mannkind shareholder would benefit Bill  . This may be another of his backpeddling moves along with exclusivity and pricing we have been subjected to. It really is hard to keep up. I support ANYTHING that benefits Mannkind but it is time to see some tangible numbers from VDEX. brotherm1, don't even bother typing it............your argument stands. |
|
|
|
Post by mnholdem on Oct 7, 2019 19:23:05 GMT -5
So we’ll let those opinions stand. Repeatedly. And since nobody can contribute any information of substance, I’m locking this hijacked thread. If new, verified information becomes available it will be reopened.
|
|
. This may be another of his backpeddling moves along with exclusivity and pricing we have been subjected to. It really is hard to keep up. I support ANYTHING that benefits Mannkind but it is time to see some tangible numbers from VDEX. brotherm1, don't even bother typing it............your argument stands. 